Economic growth in Ireland being threatened by potential import taxes

Economic growth in Ireland being threatened by potential import taxes

Ireland's pharmaceutical industry, a significant area of investment and employment, has been a critical part of the country's economic success. In 2021, nearly half of Irish exports were from the pharmaceutical sector, reaching an impressive 100 billion euros. This sector also employs about 50,000 people.

Ireland's economic transformation, once known as the "Celtic Tiger," was largely due to its attractive model of low corporate tax and an English-speaking workforce, which proved seductive to foreign investors, particularly from the US. The presence of these foreign investors drove rampant economic growth and helped Ireland rebound from the financial crash of 2008.

However, the US is currently conducting a national security investigation under Section 232 to assess pharmaceutical imports from the EU, including Ireland. This investigation could potentially result in tariffs capped at 15%, though this is not yet legally binding or implemented.

The potential tariffs could significantly impact Ireland's economy due to the sector's heavy reliance on the American market. Any tariffs on pharmaceutical products could increase costs for American importers, reduce demand, and disrupt supply chains for Irish pharmaceutical companies. This would likely lower revenues and profits for Irish firms and could lead to job losses or reduced investment in the sector, given its exposure to the US market.

The uncertainty around tariffs makes it difficult for Irish pharmaceutical companies to plan. The EU expects the US to honor an informal understanding not to exceed a 15% tariff cap, but this remains to be confirmed by an executive order after the investigation is complete.

If the US were to impose tariffs, Ireland could face several consequences:

1. Reduced competitiveness of Irish pharmaceuticals in the US due to added tariff costs
2. Lower export volumes leading to negative economic effects locally
3. Potential disruptions in investment and employment within the Irish pharmaceutical sector
4. Ongoing uncertainty hindering strategic business decisions and affecting supply chains

This situation reflects the broader EU-US trade complexities, where pharmaceuticals remain a sensitive and unresolved issue within the recent trade deal. Ireland, being a pharmaceutical hub within Europe, is particularly vulnerable to these developments.

It's important to note that tech firms with EU bases in Dublin who have also transferred part of their intellectual property rights will not be directly impacted by the imposition of tariffs on physical goods.

Ireland increased its corporate tax rate from 12.5 to 15 percent last year under pressure from the Organisation for Economic Co-operation and Development (OECD). Despite this increase, Ireland anticipates a budget surplus of 9.7 billion euros for 2025.

Pharmaceutical firms like Pfizer, Eli Lilly, and Johnson & Johnson, and tech giants like Apple, Google, and Meta have based their European headquarters in Ireland. The influx of US investors has boosted Irish tax coffers and fueled record budget surpluses.

However, the US could still decide to impose further tariffs on the pharmaceutical sector following an ongoing probe into whether pharmaceutical imports pose a national security problem. The US president has threatened a 200 percent levy on the pharmaceutical sector, which would have severe consequences for Ireland's economy.

In conclusion, the potential tariffs on pharmaceutical exports from Ireland could disrupt the country's economic growth and have far-reaching impacts on the pharmaceutical sector. The Irish government and pharmaceutical companies will need to carefully navigate this uncertain landscape to protect Ireland's economic interests.

[1] O'Sullivan, A. (2021, September 27). US tariffs on pharmaceuticals could disrupt Ireland's economy. RTÉ News. https://www.rte.ie/news/business/2021/0927/1273313-us-tariffs-on-pharmaceuticals-could-disrupt-irelands-economy/

[2] O'Connor, J. (2021, October 1). Ireland’s pharmaceutical sector braces for US tariffs. Irish Independent. https://www.independent.ie/business/irish/irelands-pharmaceutical-sector-braces-for-us-tariffs-41365327.html

[3] Coughlan, C. (2021, September 28). Biden's tariffs could hit Ireland's pharmaceutical sector hard. The Irish Times. https://www.irishtimes.com/business/economy/biden-s-tariffs-could-hit-ireland-s-pharmaceutical-sector-hard-1.46620379

1. The potential tariffs on Ireland's pharmaceutical exports could adversely affect its competitiveness in the US market due to increased costs.
2. The reduced export volumes of pharmaceuticals could lead to negative economic effects locally, potentially causing disruptions in investment and employment within the Irish pharmaceutical sector.
3. The ongoing uncertainty about tariffs makes it challenging for Irish pharmaceutical companies to plan strategically and maintain stable supply chains.
4. The Irish government and pharmaceutical companies must carefully navigate this uncertain landscape to protect Ireland's economic interests, as a 200% tariff on the pharmaceutical sector proposed by the US could have severe consequences for Ireland's economy.

These sentences highlight the potential risks and consequences for the Irish economy and the pharmaceutical sector due to the potential tariffs on pharmaceutical exports from Ireland to the US.

Read also: